Overall, these findings underline the significance of understanding the genomic landscape of ICC and the potential of targeted therapies, particularly those focused on HER2, in improving the clinical outcomes of patients with ICC. Here, ERBB2 is linked to intrahepatic cholangiocarcinoma.